32 results
Search Results
Now showing 1 - 10 of 32
Publication Metadata only Modulation of vaccine-induced CD4 T cell functional profiles by changes in components of HIV vaccine regimens in humans(2018-01-01) Franco Pissani; Bianca Schulte; Michael A. Eller; Bruce T. Schultz; Silvia Ratto-Kim; Mary Marovich; Prasert Thongcharoen; Somchai Sriplienchan; Supachai Rerks-Ngarm; Punnee Pitisuttithum; Stefan Esser; Galit Alter; Merlin L. Robb; Jerome H. Kim; Nelson L. Michael; Hendrik Streeck; International Vaccine Institute, Seoul; Massachusetts General Hospital; National Institute of Allergy and Infectious Diseases; Armed Forces Research Institute of Medical Sciences, Thailand; Thailand Ministry of Public Health; HJF; Walter Reed Army Institute of Research; Mahidol University; Faculty of Medicine, Siriraj Hospital, Mahidol University; Universitäts Klinikum Essen und Medizinische Fakultät; Mabtech, Inc.Copyright © 2018 American Society for Microbiology. All Rights Reserved. To date, six vaccine strategies have been evaluated in clinical trials for their efficacy at inducing protective immune responses against HIV infection. However, only the ALVAC..., particularly T follicular helper (Tfh) cells, are critical for effective antibody responses, most studies involving HIV vaccines have focused on humoral immunity or CD8 T cell effector responses, and little is known about the functionality and frequencyPublication Metadata only Phase I/II study of a candidate vaccine designed against the B and E subtypes of HIV-1(2004-09-01) Punnee Pitisuttithum; Phillip W. Berman; Benjaluck Phonrat; Pravan Suntharasamai; Suwanee Raktham; La Ong Srisuwanvilai; Krit Hirunras; Dwip Kitayaporn; Jaranit Kaewkangwal; Sricharoen Migasena; Haynes W. Sheppard; Elizabeth Li; Marlene Chernow; Michael L. Peterson; Riri Shibata; William L. Heyward; Donald P. Francis; Mahidol University; VaxGen, Inc.; Bangkok Metropolitan Administration; Viral Rickettsial Disease Laboratory; Novacea, Inc.; Gilead Sciences Incorporatedin humans. The optimal dose for humans in developing countries was 300 μg of each antigen (B and E). Clade E responses were measurably increased by immunizing with gp120 B/E over B alone. Using the B/E combination did not interfere with the response...-1MN) with gp120 from a subtype E virus (HIV-1A244) in alum adjuvant. The studies provide human data on the immunogenicity of various dose combination of non-subtype B vaccine antigens. The results suggest that AIDSVAX B/E is safe and immunogenicPublication Metadata only Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)(2018-07-21) Dan H. Barouch; Frank L. Tomaka; Frank Wegmann; Daniel J. Stieh; Galit Alter; Merlin L. Robb; Nelson L. Michael; Lauren Peter; Joseph P. Nkolola; Erica N. Borducchi; Abishek Chandrashekar; David Jetton; Kathryn E. Stephenson; Wenjun Li; Bette Korber; Georgia D. Tomaras; David C. Montefiori; Glenda Gray; Nicole Frahm; M. Juliana McElrath; Lindsey Baden; Jennifer Johnson; Julia Hutter; Edith Swann; Etienne Karita; Hannah Kibuuka; Juliet Mpendo; Nigel Garrett; Kathy Mngadi; Kundai Chinyenze; Frances Priddy; Erica Lazarus; Fatima Laher; Sorachai Nitayapan; Punnee Pitisuttithum; Stephan Bart; Thomas Campbell; Robert Feldman; Gregg Lucksinger; Caroline Borremans; Katleen Callewaert; Raphaele Roten; Jerald Sadoff; Lorenz Scheppler; Mo Weijtens; Karin Feddes-de Boer; Daniëlle van Manen; Jessica Vreugdenhil; Roland Zahn; Ludo Lavreys; Steven Nijs; Jeroen Tolboom; Jenny Hendriks; Zelda Euler; Maria G. Pau; Hanneke Schuitemaker; Janssen Vaccines & Prevention B.V.; Centre for the AIDS Programme of Research in South Africa; International AIDS Vaccine Initiative; Makerere University; Janssen; Massachusetts Institute of Technology; Miami Research Associates; National Institute of Allergy and Infectious Diseases; Brigham and Women's Hospital; University of Witwatersrand; HJF; Walter Reed Army Institute of Research; Mahidol University; University of Colorado at Denver; Duke University; Los Alamos National Laboratory; Royal Thai Army; Fred Hutchinson Cancer Research Center; Harvard Medical School; University of Massachusetts Medical School; Optimal Research LLC; Tekton Research; Janssen Infectious Diseases; Rwanda Zambia HIV Research Groupin humans; it elicited Env-specific binding antibody responses (100%) and antibody-dependent cellular phagocytosis responses (80%) at week 52, and T-cell responses at week 50 (83%). We also randomly assigned 72 rhesus monkeys to receive one of five different... vaccine regimens or placebo in the NHP 13-19 study. Ad26/Ad26 plus gp140 boost induced similar magnitude, durability, and phenotype of immune responses in rhesus monkeys as compared with humans and afforded 67% protection against acquisition of SHIV-SF162PPublication Metadata only Three-year follow-up of 2-dose versus 3-dose HPV vaccine(2021-01-01) Jacob Bornstein; Surita Roux; Lone Kjeld Petersen; Li Min Huang; Simon R. Dobson; Punnee Pitisuttithum; Javier Diez-Domingo; Andrea Schilling; Hany Ariffin; Richard Tytus; Richard Rupp; Shelly Senders; Eli Engel; Daron Ferris; Yae Jean Kim; Young Tae Kim; Zafer Kurugol; Oliver Bautista; Katrina M. Nolan; Sandhya Sankaranarayanan; Alfred Saah; Alain Luxembourg; National Taiwan University Hospital; Medical College of Georgia; Ege Üniversitesi; Yonsei University College of Medicine; Odense Universitetshospital; UT Medical Branch at Galveston; University of Malaya Medical Centre; Mahidol University; The University of British Columbia; Merck & Co., Inc.; Sungkyunkwan University; Bar-Ilan University; Clinica Alemana; Bayview Research Group; Synexus Clinical Research SA; Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO); Senders Pediatrics; Hamilton Medical Research GroupBACKGROUND AND OBJECTIVES: Human papillomavirus (HPV) antibody responses to the 9-valent human papillomavirus (9vHPV) vaccine among girls and boys (aged 9-14 years) receiving 2-dose regimens (months 0, 6 or 0, 12) were noninferior to a 3-dose... regimen (months 0, 2, 6) in young women (aged 16-26 years) 4 weeks after last vaccination in an international, randomized, open-label trial (NCT01984697). We assessed response durability through month 36. METHODS: Girls received 2 (months 0 and 6 [0, 6]: nPublication Metadata only Human immunodeficiency virus type 1 elite neutralizers: Individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm(2009-07-01) Melissa D. Simek; Wasima Rida; Frances H. Priddy; Pham Pung; Emily Carrow; Dagna S. Laufer; Jennifer K. Lehrman; Mark Boaz; Tony Tarragona-Fiol; George Miiro; Josephine Birungi; Anton Pozniak; Dale A. McPhee; Olivier Manigart; Etienne Karita; André Inwoley; Walter Jaoko; Jack DeHovitz; Linda Gail Bekker; Punnee Pitisuttithum; Robert Paris; Laura M. Walker; Pascal Poignard; Terri Wrin; Patricia E. Fast; Dennis R. Burton; Wayne C. Koff; International AIDS Vaccine Initiative; Monogram Biosciences; Scripps Research Institute; Emory University; Uganda Virus Research Institute; National Center in HIV-1 Epidemiology and Clinical Research; St Stephen's AIDS Trust; Advanced Bioadjuvants; University of Nairobi; SUNY Downstate Medical Center; University of Cape Town; Mahidol University; Armed Forces Research Institute of Medical Sciences, Thailand; Imperial College London; Sanofi PasteurThe development of a rapid and efficient system to identify human immunodeficiency virus type 1 (HIV-1)-infected individuals with broad and potent HIV-1-specific neutralizing antibody responses is an important step toward the discovery of critical... neutralization targets for rational AIDS vaccine design. In this study, samples from HIV-1-infected volunteers from diverse epidemiological regions were screened for neutralization responses using pseudovirus panels composed of clades A, B, C, and DPublication Metadata only HLA class II restriction of HIV-1 clade-specific neutralizing antibody responses in ethnic Thai recipients of the RV144 prime-boost vaccine combination of ALVAC-HIV and AIDSVAX ® B/E(2012-01-20) Robert Paris; Sasitorn Bejrachandra; Prasert Thongcharoen; Sorachai Nitayaphan; Punnee Pitisuttithum; Anna Sambor; Sanjay Gurunathan; Donald Francis; Silvia Ratto-Kim; Chitraporn Karnasuta; Mark S. de Souza; Victoria R. Polonis; Arthur E. Brown; Jerome H. Kim; Henry A. Stephens; Armed Forces Research Institute of Medical Sciences, Thailand; Faculty of Medicine, Siriraj Hospital, Mahidol University; Mahidol University; United States Military HIV Research Program/Henry M. Jackson Foundation; Sanofi Pasteur; Global Solutions for Infectious Diseases; Walter Reed Army Institute of Research; UCLImmune responses to vaccines may be influenced or associated with allelic variants of host genes such as those encoding human leucocyte antigens (HLA). We have molecularly determined the HLA class II DR and DQ gene, allele and haploype profiles... in HIV-1 negative ethnic Thai recipients of an HIV-1 prime boost vaccine regimen, designed to induce neutralizing antibody (NAb) responses to HIV-1 CRF01_AE. Non-response to vaccine associated with DRB1*11 (3/32 responders vs. 7/13 non-responders, p c =0Publication Metadata only A live attenuated H5N2 prime- inactivated H5N1 boost vaccination induces influenza virus hemagglutinin stalk specific antibody responses(2020-01-22) Alita Kongchanagul; Karnyart Samnuan; Ponthip Wirachwong; Somchaiya Surichan; Pilaipan Puthavathana; Punnee Pitisuttithum; Kobporn Boonnak; Mahidol University; Government Pharmaceutical Organization© 2019 Elsevier Ltd Background: The emergence and spread of highly pathogenic avian influenza (H5N1) viruses have raised global concerns of a possible human pandemic, spurring efforts towards H5N1 influenza vaccine development and improvements... in vaccine administration methods. We previously showed that a prime-boost vaccination strategy induces robust and broadly cross-reactive antibody responses against the hemagglutinin globular head domain. Here, we specifically measure antibodies againstPublication Metadata only HIV-specific antibody-dependent phagocytosis matures during HIV infection(2014-01-01) Fernanda Ana-Sosa-Batiz; Angus P.R. Johnston; Haiyin Liu; Robert J. Center; Supachai Rerks-Ngarm; Punnee Pitisuttithum; Sorachai Nitayaphan; Jaranit Kaewkungwal; Jerome H. Kim; Nelson L. Michael; Anthony D. Kelleher; Ivan Stratov; Stephen J. Kent; Marit Kramski; University of Melbourne; Monash University; Burnet Institute; Thailand Ministry of Public Health; Mahidol University; Armed Forces Research Institute of Medical Sciences, Thailand; Walter Reed Army Institute of Research; University of New South Wales (UNSW) Australiaduring HIV infection, a significant increase in ADP responses in all 31 subjects studied was detected (P<0.001). However, when we tested 30 HIV-negative human subjects immunised with the Canarypox/gp120 vaccine regimen (subjects from the RV144 trial) we...© 2014 Australasian Society for Immunology Inc. All rights reserved. Antibody-dependent phagocytosis (ADP) is a potentially important immune mechanism to clear HIV. How HIV-specific ADP responses mature during HIV infection or in responsePublication Metadata only HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition(2015-07-15) Heather A. Prentice; Georgia D. Tomaras; Daniel E. Geraghty; Richard Apps; Youyi Fong; Philip K. Ehrenberg; Morgane Rolland; Gustavo H. Kijak; Shelly J. Krebs; Wyatt Nelson; Allan DeCamp; Xiaoying Shen; Nicole L. Yates; Susan Zolla-Pazner; Sorachai Nitayaphan; Supachai Rerks-Ngarm; Jaranit Kaewkungwal; Punnee Pitisuttithum; Guido Ferrari; M. Juliana McElrath; David C. Montefiori; Robert T. Bailer; Richard A. Koup; Robert J. O'Connell; Merlin L. Robb; Nelson L. Michael; Peter B. Gilbert; Jerome H. Kim; Rasmi Thomas; Walter Reed Army Institute of Research; HJF; Duke University School of Medicine; Fred Hutchinson Cancer Research Center; Leidos Inc.; NYU School of Medicine; Armed Forces Research Institute of Medical Sciences, Thailand; Thailand Ministry of Public Health; Mahidol University; National Institute of Allergy and Infectious Diseases; Inova Fairfax Medical Campus© 2015, American Association for the Advancement of Science. All rights reserved. In the RV144 vaccine trial, two antibody responses were found to correlate with HIV-1 acquisition. Because human leukocyte antigen (HLA) class II-restricted CD4...+T cells are involved in antibody production, we tested whether HLA class II genotypes affected HIV-1-specific antibody levels and HIV-1 acquisition in 760 individuals. Indeed, antibody responses correlated with acquisition only in the presence of singlePublication Metadata only Cross-reactivity of anti-HIV-1 T cell immune responses among the major HIV-1 clades in HIV-1-positive individuals from 4 continents(2005-05-01) Paul M. Coplan; Swati B. Gupta; Sheri A. Dubey; Punnee Pitisuttithum; Alex Nikas; Bernard Mbewe; Efthyia Vardas; Mauro Schechter; Esper G. Kallas; Dan C. Freed; Tong Ming Fu; Christopher T. Mast; Pilaipan Puthavathana; James Kublin; Kelly Brown Collins; John Chisi; Richard Pendame; Scott J. Thaler; Glenda Gray; James Mcintyre; Walter L. Straus; Jon H. Condra; Devan V. Mehrotra; Harry A. Guess; Emilio A. Emini; John W. Shiver; Merck Research Laboratories; Mahidol University; Malawi College of Medicine; Ministry of Population and Health; Universidade Federal do Rio de Janeiro; Universidade Federal de Sao Paulo; University of Witwatersrand; Intl. Partnership for Microbicides; The University of North Carolina at Chapel Hill; International AIDS Vaccine Initiative; International Partnership for MicrobicidesBackground. The genetic diversity of human immunodeficiency virus type 1 (HIV-1) raises the question of whether vaccines that include a component to elicit antiviral T cell immunity based on a single viral genetic clade could provide cellular immune... protection against divergent HIV-1 clades. Therefore, we quantified the cross-clade reactivity, among unvaccinated individuals, of anti-HIV-1 T cell responses to the infecting HIV-1 clade relative to other major circulating clades. Methods. Cellular immune